What does Camizestrant (Etcamah) do in plain English—and how does it work inside your body?
Camizestrant is an FDA-regulated FDA Prescription Therapeutic Agent (RxNorm RxCUI 2752687). Mechanistically, 12.1 Mechanism of Action Camizestrant is an estrogen receptor (ER) antagonist. In vitro, camizestrant binds to the ligand binding domain of ERα, antagonizing the activity of ERα encoded by both wild-type ESR1 and mutated ESR1 and inducing proteasome-dependent degradation of ERα, without agonizing ERα. Camizestrant demonstrated anti-tumor activity in ER-positive cell lines, in vitro, and patient derived xenograft (PDX) models, in vivo, including those with wild-type or mutated ESR1 genes. [1][2].
When your doctor writes a prescription for Camizestrant (RxNorm RxCUI 2752687, also dispensed under brand names including Etcamah), the goal is to target the root physiological pathway driving your condition rather than just masking surface symptoms [1]. According to the official FDA DailyMed package insert, 12.1 Mechanism of Action Camizestrant is an estrogen receptor (ER) antagonist. In vitro, camizestrant binds to the ligand binding domain of ERα, antagonizing the activity of ERα encoded by both wild-type ESR1 and mutated ESR1 and inducing proteasome-dependent degradation of ERα, without agonizing ERα. Camizestrant demonstrated anti-tumor activity in ER-positive cell lines, in vitro, and patient derived xenograft (PDX) models, in vivo, including those with wild-type or mutated ESR1 genes. [2].
Across real-world patient logs on dotMD (93% positive worth-it rating), patients do best when they understand both what the medication is doing on day 1 and how long it takes to reach steady-state protection [3].
Check the imprint code on your Camizestrant tablet bottle and confirm with your pharmacist that it matches your prescribed strength (75 mg/1 Tablet, Film Coated, 75 mg).